| review article | Q7318358 |
| scholarly article | Q13442814 |
| P8978 | DBLP publication ID | journals/sensors/GoshoNS12 |
| P356 | DOI | 10.3390/S120708966 |
| P932 | PMC publication ID | 3444086 |
| P698 | PubMed publication ID | 23012528 |
| P5875 | ResearchGate publication ID | 231212246 |
| P50 | author | Kengo Nagashima | Q40876524 |
| P2093 | author name string | Masahiko Gosho | |
| Yasunori Sato | |||
| P2860 | cites work | UGT1A1 gene variations and irinotecan treatment in patients with metastatic colorectal cancer | Q24648015 |
| RETRACTED: A genomic approach to colon cancer risk stratification yields biologic insights into therapeutic opportunities | Q24651467 | ||
| Do multiple outcome measures require p-value adjustment? | Q24796748 | ||
| Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. | Q27824766 | ||
| Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer | Q27824847 | ||
| Biomarkers and surrogate endpoints: preferred definitions and conceptual framework | Q28203935 | ||
| The challenge of subgroup analyses--reporting without distorting | Q28235374 | ||
| Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan | Q28249001 | ||
| Biomarker-adaptive threshold design: a procedure for evaluating treatment with possible biomarker-defined subset effect. | Q51911724 | ||
| A comparison of two phase I trial designs. | Q52371181 | ||
| Statistics in practice. Comparing the means of several groups. | Q52656150 | ||
| Approaches to evaluation of treatment effect in randomized clinical trials with genomic subset | Q56528613 | ||
| Customizing Cisplatin Based on Quantitative Excision Repair Cross-Complementing 1 mRNA Expression: A Phase III Trial in Non–Small-Cell Lung Cancer | Q59274335 | ||
| Multiple testing in clinical trials | Q67902021 | ||
| Surrogate endpoints in clinical trials: cancer | Q69620765 | ||
| ICH Harmonised Tripartite Guideline. Statistical principles for clinical trials. International Conference on Harmonisation E9 Expert Working Group | Q73110915 | ||
| Analytical validation of the Oncotype DX genomic diagnostic test for recurrence prognosis and therapeutic response prediction in node-negative, estrogen receptor-positive breast cancer | Q80226703 | ||
| Evaluating the efficiency of targeted designs for randomized clinical trials | Q80901366 | ||
| Adaptive signature design: an adaptive clinical trial design for generating and prospectively testing a gene expression signature for sensitive patients | Q81460457 | ||
| The cross-validated adaptive signature design | Q82478799 | ||
| The efficiency of clinical trial designs for predictive biomarker validation | Q84461627 | ||
| Biomarkers in cancer staging, prognosis and treatment selection | Q28278305 | ||
| A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer | Q28297827 | ||
| Subgroup analysis and other (mis)uses of baseline data in clinical trials | Q30588628 | ||
| Clinical trial designs for predictive marker validation in cancer treatment trials | Q33213015 | ||
| Assessing the clinical impact of prognostic factors: when is "statistically significant" clinically useful? | Q33538461 | ||
| Bayesian adaptive design for targeted therapy development in lung cancer--a step toward personalized medicine | Q33827699 | ||
| Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer | Q33996115 | ||
| Randomized clinical trials with biomarkers: design issues | Q34024227 | ||
| Clinical trial designs for predictive biomarker validation: one size does not fit all. | Q34097089 | ||
| Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxicity: a pharmacogenetic analysis. | Q34130450 | ||
| A genomic strategy to refine prognosis in early-stage non-small-cell lung cancer. | Q34555834 | ||
| Acute promyelocytic leukemia: from highly fatal to highly curable | Q34755208 | ||
| Cytochrome p-450 polymorphisms and response to clopidogrel | Q34910228 | ||
| Clinical biomarkers in drug discovery and development | Q35167912 | ||
| Development of the 21-gene assay and its application in clinical practice and clinical trials | Q37079600 | ||
| The use of genomics in clinical trial design | Q37284262 | ||
| Clinical trial designs for predictive biomarker validation: theoretical considerations and practical challenges. | Q37325013 | ||
| Bayesian adaptive randomization designs for targeted agent development | Q37415504 | ||
| Integrating biomarkers in clinical trials | Q37853183 | ||
| A statistician's perspective on biomarkers in drug development. | Q37967642 | ||
| Trial assessing individualized options for treatment for breast cancer: the TAILORx trial | Q40036322 | ||
| Tumor marker utility grading system: a framework to evaluate clinical utility of tumor markers | Q40923195 | ||
| Surrogate end points in clinical trials: are we being misled? | Q41117631 | ||
| Surrogate endpoints in clinical trials: definition and operational criteria | Q41310696 | ||
| Randomized phase III clinical trial designs for targeted agents | Q42165255 | ||
| Statistical aspects of prognostic factor studies in oncology | Q42388377 | ||
| B-type natriuretic peptide predicts sudden death in patients with chronic heart failure | Q43703424 | ||
| Relevance of different UGT1A1 polymorphisms in irinotecan-induced toxicity: a molecular and clinical study of 75 patients | Q45009159 | ||
| The false discovery rate: a key concept in large-scale genetic studies. | Q46036490 | ||
| Comparison of effect sizes associated with biomarkers reported in highly cited individual articles and in subsequent meta-analyses | Q46207178 | ||
| P275 | copyright license | Creative Commons Attribution | Q6905323 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 7 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | statistics | Q12483 |
| biomarker | Q864574 | ||
| research design | Q1438035 | ||
| biomedical investigative technique | Q66648976 | ||
| P304 | page(s) | 8966-8986 | |
| P577 | publication date | 2012-06-29 | |
| P1433 | published in | Sensors | Q3478643 |
| P1476 | title | Study designs and statistical analyses for biomarker research | |
| P478 | volume | 12 |
| Q52721984 | A Critical Evaluation of Wet Biomarkers for Huntington's Disease: Current Status and Ways Forward. |
| Q34357303 | Academic College of Emergency Experts in India's INDO-US Joint Working Group and OPUS12 Foundation Consensus Statement on Creating A Coordinated, Multi-Disciplinary, Patient-Centered, Global Point-of-Care Biomarker Discovery Network |
| Q91757571 | Adaptive Signature Design- review of the biomarker guided adaptive phase -III controlled design |
| Q33934232 | Adjusting for misclassification in a stratified biomarker clinical trial. |
| Q47417612 | Advancing cancer drug development through precision medicine and innovative designs |
| Q59137422 | Age stratification corrects bias in estimated hazard of genotype for Alzheimer's disease |
| Q57022879 | Antecedents of Obesity Among Children Born Extremely Preterm |
| Q26766584 | Biomarker-Guided Adaptive Trial Designs in Phase II and Phase III: A Methodological Review |
| Q37731264 | Biomarker-Guided Non-Adaptive Trial Designs in Phase II and Phase III: A Methodological Review |
| Q37529483 | Can a combined screening/treatment programme prevent premature failure of renal transplants due to chronic rejection in patients with HLA antibodies: study protocol for the multicentre randomised controlled OuTSMART trial |
| Q26795767 | Clinical Neuropathology practice guide 5-2015: MGMT methylation pyrosequencing in glioblastoma: unresolved issues and open questions |
| Q36534713 | Clinical trial designs incorporating predictive biomarkers. |
| Q41779502 | Cognitive Effects of Adenotonsillectomy for Obstructive Sleep Apnea |
| Q46294199 | Exploring carotid sonographic parameters associated with stroke risk among hypertensive stroke patients compared to hypertensive controls |
| Q34343547 | Exploring the human plasma proteome for humoral mediators of remote ischemic preconditioning--a word of caution |
| Q28080102 | Genome-wide epigenomic profiling for biomarker discovery |
| Q38148601 | Impact of biomarkers on clinical trial risk |
| Q47290509 | Informatics for cancer immunotherapy |
| Q47688852 | Monitoring disease progression with plasma creatinine in amyotrophic lateral sclerosis clinical trials |
| Q38675644 | Optimizing drug development in oncology by clinical trial simulation: Why and how? |
| Q26778319 | Potential Biomarkers of Fat Loss as a Feature of Cancer Cachexia |
| Q90168559 | Qualifying antibodies for image-based immune profiling and multiplexed tissue imaging |
| Q55293579 | Statistical Basic Steps to Be Considered on Planning a Research. |
| Q98736011 | Validity of Serum miRNA 93 and miRNA 191 to Reduce Unnecessary Computed Tomography in Patients With Mild Head Trauma |
Search more.